Rocket Doctor AI January 2026 Update | CEO Dr. Essam Hamza $AIRDF скачать в хорошем качестве

Rocket Doctor AI January 2026 Update | CEO Dr. Essam Hamza $AIRDF

Rocket Doctor AI January 2026 Update | CEO Dr. Essam Hamza I sat down with Dr. Essam Hamza, CEO of Rocket Doctor AI (CSE: AIDR | OTC: AIRDF), to discuss the company's rapid execution over the past 60 days and what investors should watch for in 2026. TOPICS COVERED: 0:00 Intro 0:15 Prioritizing across multiple initiatives 1:10 U.S. expansion: 13M+ lives in-network, capital allocation 2:45 Advertising spend ramping in January 3:45 Investor demand: raise upsized from $3M → $5.2M 5:35 CAN Health Alberta CDSS pilot & fixing healthcare supply/demand 9:10 TMU medical school partnership 10:40 What makes Rocket Doctor's AI safer (no hallucinations, clinically validated) 13:25 Biggest constraint on growth 14:55 What to watch over the next 6 months KEY METRICS: 13M+ U.S. covered lives 700,000+ patient visits to date 300+ physicians on platform ~89% gross margins C$5.2M raised (Jan 2026) Disclaimer 45 Degrees, Inc (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Rocket Doctor AI will make a one-time payment of $180,000 USD and 400,000 options at .45 CAD to provide marketing services for a term of 6 months. We or certain non-arm's length parties own 30000 common shares of Rocket Doctor AI. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable, but we cannot guarantee it. Forward Looking Statements This article contains forward-looking statements about Treatment.com AI Inc., which are identified by terms such as "anticipate," "expect," and "project." These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article's publication date and we undertake no obligation to update.